TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Sleep Hygiene Counseling: A Randomized Controlled Trial
Brief Summary: This study will evaluate the efficacy of an intervention to improve quality and duration of self-regulated nighttime sleep (the amount of time the child maintains a combination of uninterrupted sleep, quiet wakefulness, and re-initiation of sleep without parental intervention).


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep hygiene counseling | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sleep hygiene counseling; Assigned to Arm(s): Intervention group
B: Arm Label: 4-Health Educational curriculum; Type: EXPERIMENTAL; Interventions: Behavioral: 4-Health Educational curriculum | Arm Label: Healthy Living Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Living Information | Intervention Type: BEHAVIORAL; Name: 4-Health Educational curriculum; Assigned to Arm(s): 4-Health Educational curriculum | Intervention Type: BEHAVIORAL; Name: Healthy Living Information; Assigned to Arm(s): Healthy Living Information
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educational strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy | Arm Label: Screening strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Screening strategy | Arm Label: Environmental strategy; Type: EXPERIMENTAL; Interventions: Other: Environmental strategy | Arm Label: Educational and Screening strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Behavioral: Screening strategy | Arm Label: Screening and Environmental strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Screening strategy, Other: Environmental strategy | Arm Label: Educational and Environmental strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Other: Environmental strategy | Arm Label: the three strategies; Type: EXPERIMENTAL; Interventions: Behavioral: Educational strategy, Behavioral: Screening strategy, Other: Environmental strategy | Intervention Type: BEHAVIORAL; Name: Educational strategy; Assigned to Arm(s): Educational and Environmental strategies, Educational and Screening strategies, Educational strategy, the three strategies | Intervention Type: BEHAVIORAL; Name: Screening strategy; Assigned to Arm(s): Educational and Screening strategies, Screening and Environmental strategies, Screening strategy, the three strategies | Intervention Type: OTHER; Name: Environmental strategy; Assigned to Arm(s): Educational and Environmental strategies, Environmental strategy, Screening and Environmental strategies, the three strategies
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Vaasa Childhood Obesity Primary Prevention Study | Intervention Type: BEHAVIORAL; Name: Vaasa Childhood Obesity Primary Prevention Study; Assigned to Arm(s): Lifestyle counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Multi-pronged Intervention to Address Prevention of Violence in Zambia
Brief Summary: This study evaluates the effectiveness of a multi-pronged intervention in reducing and preventing violence against women and children compared to a treatment as usual control group among families living in Lusaka, Zambia.


Options:
A: Arm Label: Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention | Arm Label: MET+CBT Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy (MET) Intervention, Behavioral: Cognitive Behavioral Therapy (CBT) Intervention | Arm Label: Assessment-Only Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Intervention; Assigned to Arm(s): Brief Intervention | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy (MET) Intervention; Assigned to Arm(s): MET+CBT Intervention | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT) Intervention; Assigned to Arm(s): MET+CBT Intervention
B: Arm Label: CETA; Type: EXPERIMENTAL; Interventions: Behavioral: CETA | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: CETA; Assigned to Arm(s): CETA | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual
C: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention
D: Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Observation | Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Other: ASSIST-linked brief intervention for hazardous and harmful substance use. | Intervention Type: OTHER; Name: ASSIST-linked brief intervention for hazardous and harmful substance use.; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Observation; Assigned to Arm(s): Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating a Novel Cognitive-Behavioral Online Depression Intervention for Persons With Epilepsy (Desiconnect): Randomized Controlled Trial
Brief Summary: The trial aims to evaluate the effectiveness of a novel internet intervention (Desiconnect), which was designed to introduce relevant cognitive-behavioral therapy (CBT) techniques to Persons with Epilepsy (PwE) and comorbid depression. Therefore, 200 PwE and a current depressive disorder (major depressive disorder or dysthymic disorder) will be recruited and randomized to two groups: (1) a control group, in which they may engage with any epilepsy treatment (Care-as-Usual, CAU) and receive access to Desiconnect after a delay of three months (i.e., CAU/wait list control group), or (2) to a treatment group that immediately receives six-month access to Desiconnect and may also use CAU. The primary outcome measure is the depression scale of the Patient Health Questionnaire (PHQ-9), collected at three months post-baseline.


Options:
A: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
B: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Arm Label: Standardized educational plan; Type: EXPERIMENTAL; Interventions: Other: Standardized educational plan | Intervention Type: OTHER; Name: Standardized educational plan; Assigned to Arm(s): Standardized educational plan | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
C: Arm Label: Desiconnect; Type: EXPERIMENTAL; Interventions: Behavioral: Desiconnect, Other: CAU | Arm Label: Care-as-Usual (CAU) / wait list; Type: ACTIVE_COMPARATOR; Interventions: Other: CAU | Intervention Type: BEHAVIORAL; Name: Desiconnect; Assigned to Arm(s): Desiconnect | Intervention Type: OTHER; Name: CAU; Assigned to Arm(s): Care-as-Usual (CAU) / wait list, Desiconnect
D: Arm Label: Deprexis; Type: EXPERIMENTAL; Interventions: Behavioral: Deprexis | Arm Label: Wait-list; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Deprexis, Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Deprexis; Assigned to Arm(s): Deprexis, Wait-list | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Brief Summary: To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis


Options:
A: Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate
B: Arm Label: OMB 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
C: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GA 40 mg / GA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate (GA) | Arm Label: Placebo / GA 40 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glatiramer acetate (GA), Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer acetate (GA); Assigned to Arm(s): GA 40 mg / GA 40 mg, Placebo / GA 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / GA 40 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis
Brief Summary: To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis


Options:
A: Arm Label: OMB 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
B: Arm Label: Placebo + GA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide), Drug: Glatiramer Acetate (GA) | Arm Label: Teriflunomide 7 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate (GA) | Arm Label: Teriflunomide 14 mg + GA; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide, Drug: Glatiramer Acetate (GA) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo + GA | Intervention Type: DRUG; Name: Glatiramer Acetate (GA); Assigned to Arm(s): Placebo + GA, Teriflunomide 14 mg + GA, Teriflunomide 7 mg + GA
C: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Brief Summary: To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a
C: Arm Label: OMG 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
D: Arm Label: fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: fingolimod 0.25mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: glatiramer acetate 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate | Intervention Type: DRUG; Name: fingolimod; Assigned to Arm(s): fingolimod 0.25mg, fingolimod 0.5 mg | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): glatiramer acetate 20 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Brief Summary: To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis


Options:
A: Arm Label: OMG 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
B: Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo
C: Arm Label: GA 20 mg/mL every day; Type: ACTIVE_COMPARATOR; Interventions: Drug: GA 20 mg/mL | Arm Label: GA 40 mg/mL 3 times a week; Type: EXPERIMENTAL; Interventions: Drug: GA 40 mg/mL | Intervention Type: DRUG; Name: GA 20 mg/mL; Assigned to Arm(s): GA 20 mg/mL every day | Intervention Type: DRUG; Name: GA 40 mg/mL; Assigned to Arm(s): GA 40 mg/mL 3 times a week
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
Brief Summary: Aim of this study is to evaluate in a population of old osteoporotic chronic kidney disease females the effect of denosumab:

* on bone mineral density (femoral T-score) at 24 months
* on bone mineral density evolution (femoral T-score) after 24 months of follow-up
* on bone mineral density evolution (lumbar T-score) after 24 months of follow-up
* on coronary and abdominal aorta calcification scores evolution after 24 months of follow-up
* on parameters of bone remodelling (OPG, RANKL, sclerostin, DKK-1), of mineral and calcium metabolism (FGF23 Ct, Klotho, PTH, 25(OH) vitamin D3, phosphorus, calcium, bone alklaline phosphatase, osteocalcin, CTX), of inflammation (CRP) after 24 months of follow-up
* on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of follow-up
* the tolerance after 24 months of follow-up


Options:
A: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl (placebo) | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: NaCl (placebo); Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: alendronate (Fosamax); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: alendronate; Assigned to Arm(s): N/A
D: Arm Label: Romosozumab; Type: EXPERIMENTAL; Interventions: Drug: Romosozumab, Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Denosumab | Intervention Type: DRUG; Name: Romosozumab; Assigned to Arm(s): Romosozumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Placebo, Romosozumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Family Networks (FaNs) for Children With Developmental Disorders and Delays Program: A Cluster Randomized Control Trial
Brief Summary: Over 6% of children in Pakistan suffer from a developmental disorder (intellectual disability or Autistic spectrum disorder) and most receive no intervention.In an earlier proof of concept study, the investigators integrated social, technological and business innovations to develop and successfully pilot a sustainable service for such children in one rural population of 30,000. Affected families were identified through a mobile phone-based interactive voice response system, and organised into family networks. 'Champion' family volunteers were trained in evidence-based interventions. A Tablet-based android application was developed for training, monitoring and supervision of the champions, based on the World Health Organization's guidelines. The champions delivered the intervention to other families in the network. The project was sustainable and demonstrated significant improvements in the lives of children and their families in the first 6 months of its operation. The investigators are scaling-up this intervention to a population of 1 million. The investigators aim to evaluate the effectiveness and cost effectiveness of the scaled-up programme using cluster randomized control trial nested within the scale-up study.


Options:
A: Arm Label: Youth microfinance only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: adult microfinance | Arm Label: youth and adult micro finance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Youth microfinance only | Arm Label: adult microfinance; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: youth and adult micro finance | Intervention Type: BEHAVIORAL; Name: adult microfinance; Assigned to Arm(s): Youth microfinance only | Intervention Type: BEHAVIORAL; Name: Youth microfinance only; Assigned to Arm(s): youth and adult micro finance | Intervention Type: BEHAVIORAL; Name: youth and adult micro finance; Assigned to Arm(s): adult microfinance
B: Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Family Networks program; Type: EXPERIMENTAL; Interventions: Behavioral: Family networks program | Intervention Type: BEHAVIORAL; Name: Family networks program; Assigned to Arm(s): Family Networks program
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ACT Intervention; Type: EXPERIMENTAL; Interventions: Other: ACT | Intervention Type: OTHER; Name: ACT; Assigned to Arm(s): ACT Intervention
D: Arm Label: Trickle Up; Type: EXPERIMENTAL; Interventions: Behavioral: Trickle Up | Arm Label: Trickle Up Plus; Type: EXPERIMENTAL; Interventions: Behavioral: Trickle Up Plus | Arm Label: Wait-list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trickle Up; Assigned to Arm(s): Trickle Up | Intervention Type: BEHAVIORAL; Name: Trickle Up Plus; Assigned to Arm(s): Trickle Up Plus

Answer: B